ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 16
This article first appeared on GuruFocus.
ETF flows pulled a net $200.9 million out of Gilead Sciences (GILD) on Friday. More funds traded the other way, with 31 ETFs buying versus 16 selling, but the sellers’ amounts were larger. The move snapped a run of four straight days of net buying, including $25.6 million on Oct. 13 and $15.9 million on Oct. 12. It was the first day of net selling in that stretch.
See all ETF and guru trades in GILD on its GILD guru trades page.
Which ETFs sold GILD on Friday?
The largest sellers by dollar value were FTCS ($175.2 million), QQQ ($28.2 million) and IBB ($9.8 million). In all, 31 ETFs added shares and 16 cut them.
FTCS accounted for the bulk of the selling, off 1,121,974 shares for a $175.2 million decline. QQQ trimmed 180,480 shares worth $28.2 million, while IBB cut 62,777 shares ($9.8 million) and FBT reduced 58,960 shares ($9.2 million). Smaller reductions came from QLD, LABU, RSP and IWD. Gilead is a Healthcare company in the Drug Manufacturers – General industry with a market cap of $189.8 billion.
Have ETFs been buying or selling GILD lately?
Over the last 5 reported days, ETFs were net buyers on 4 and net sellers on 1, so the recent trend is mostly buying.
What does GILD do?
Gilead Sciences is a biopharmaceutical company best known for its antiviral franchises. It dominates HIV treatment and prevention with Biktarvy, the world’s leading HIV regimen, and Descovy, and launched lenacapavir (Yeztugo), a twice-yearly injectable for HIV prevention regarded as a breakthrough in the field.
Gilead reported trailing-12-month revenue of $30.54 billion, up 6.5% over one year, with a gross margin of 79.7% and a net margin of -10.6%. Its P/B ratio is 16.06 and P/S is 6.27, with a market cap of $189.8 billion. The GF Score is 71, and GF Value of $107.12 compares with a price of $153.07. The dividend yield is 2.23% and the year-to-date return is 26.95%.